Get started
Author

Stephanie M. Burnett

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
2019 · Douglas H Brand, Alison C Tree, et al. · The Lancet Oncology · 550
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
2022 · Alison C Tree, Peter Ostler, et al. · The Lancet Oncology · 318
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
2024 · Nicholas van As, Clare Griffin, et al. · New England Journal of Medicine · 287
PDF
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
2013 · S Nicholson, E Hall, et al. · British Journal of Cancer · 137
PDF
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial
2024 · Nicholas van As, Binnaz Yasar, et al. · European Urology · 73
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial
2025 · Alison C Tree, Victoria Hinder, et al. · The Lancet Oncology · 43
PDF
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
2018 · John D. Kelly, Wei Shen Tan, et al. · European Urology · 38
PDF
PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.
2023 · Nicholas John Van As, Alison Tree, et al. · Journal of Clinical Oncology · 31
PDF
PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
2019 · Nicholas John Van As, Douglas Brand, et al. · Journal of Clinical Oncology · 29
The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.
2022 · Curtis Alvin Pettaway, Steve Nicholson, et al. · Journal of Clinical Oncology · 18
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).
2018 · Lisa M. Pickering, Holly Tovey, et al. · Journal of Clinical Oncology · 17
HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy
2025 · Sian Cooper, Rosalyne L. Westley, et al. · International Journal of Radiation Oncology*Biology*Physics · 13
PDF
VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).
2018 · Lisa M. Pickering, Holly Tovey, et al. · Journal of Clinical Oncology · 13
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis
2021 · Steve Nicholson, Holly Tovey, et al. · British Journal of Cancer · 12
PDF
Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms
2015 · Ihtisham Malik, Stephanie Burnett, et al. · Trials · 10
PDF
Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)
2025 · Sian Cooper, Steve Nicholson, et al. · International Journal of Radiation Oncology*Biology*Physics · 5
3395: Acute toxicity from PACE-C comparing Stereotactic Body Radiotherapy (SBRT) with moderate hypofractionation (MHRT)
2024 · Alison Tree, Victoria Hinder, et al. · Radiotherapy and Oncology · 4
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes
2024 · Sarah Benafif, Ann-Britt Jones, et al. · BJC Reports · 4
PDF
OC-0289 Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy)
2021 · A.C. Tree, E. Hall, et al. · Radiotherapy and Oncology · 4
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
2025 · Pasquale Rescigno, Maria Dolores Fenor de la Maza, et al. · European Urology Oncology · 3
PDF
Implementing electronic data capture (EDC) training for site staff
2015 · Mark Webster-Smith, Claire Paulding, et al. · Trials · 3
PDF
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial
2026 · Sian Cooper, Jaymini Patel, et al. · European Urology · 2
Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).
2024 · Pasquale Rescigno, Maria Dolores Fenor de la Maza, et al. · Journal of Clinical Oncology · 2
PDF
Design considerations when transitioning from paper case report forms (CRFS) to electronic data capture (EDC)
2015 · Rebecca Lewis, Leona Batten, et al. · Trials · 2
PDF
7110 POSTER DISCUSSION A Phase II Trial of Docetaxel, Cisplatin, 5-Fluorouracil (TPF) in Locally Advanced and Metastatic Carcinoma of the Penis (CRUK/09/001)
2011 · A. Bahl, S. Nicholson, et al. · European Journal of Cancer · 2
Works count: 28
Citation count: 1,622
H-index: 13
I10-index: 15
Year
Topic
Type